Fosun Pharma subsidiary gets green light for clinical trial

Shanghai Fosun Pharmaceutical Group (Fosun Pharma, SSE:600196) announced that its holding subsidiary, Fosun Pharmaceutical (Xuzhou) Co., Ltd., has obtained approval from the National Medical Products Administration to conduct clinical trials for CMC-2310 oral dissolving film. CMC-2310, independently developed by the group, is intended for the treatment of schizophrenia in adults and children aged 13 and above. As of March 2025, the cumulative R&D investment for CMC-2310 is approximately CNY 7.25 million. A medicine with the same active ingredients was approved for listing in mainland China in 2024. Fosun Pharma cautioned investors regarding the risks associated with new drug development, including potential trial termination due to safety or efficacy concerns.